Concerto HealthAI, a Boston, MA-based provider of Real-World Data (RWD) and enterprise AI technology solutions for Precision Oncology, raised $150m in Series B financing.
The round was led by Declaration Partners with participation from Maverick Ventures, AllianceBernstein PCI, and SymphonyAI Group. As part of the transaction, Andrew Goldfarb, partner at Declaration Partners, and Leif Pedersen, senior operating partner at SymphonyAI Group, will join Concerto HealthAI’s board. Romesh Wadhwani, founder and CEO of SymphonyAI Group, will continue as executive chairman, and Jeff Elton, PhD, CEO of Concerto HealthAI as board member.
The funding will support the company’s continued innovation in RWD and technology products and services for regulatory and non-regulatory applications, expansion into adjacent therapy areas, and commercial patient solutions.
Concerto HealthAI is a technology leader in Real-World Data (RWD) and AI solutions for precision oncology, which has assembled a clinical network through partnerships with community oncology networks and exclusive licensing with CancerLinQ LLC, a nonprofit subsidiary of the American Society of Clinical Oncology (ASCO). These partnerships and relationships are across all major Electronic Medical Record environments, inclusive of next generation sequencing diagnostic information and Patient Reported Outcomes. The company’s engineers use case-aligned, AI-enriched, validated, and production-ready RWD products and complementary AI-enabled cloud technologies for precision research and patient solutions.
Concerto HealthAI has also launched a new version of eurekaHealth, which combines integrated RWD and advanced AI machine learning.